联合他类药物和尼亚疗法重塑高密度脂蛋白蛋白质组
Pattie S Green1, Tomas Vaisar, Subramaniam Pennathur
1Department of Medicine, University of Washington, Seattle, WA, USA. psgreen@u.washington.edu
Circulation
|September 4, 2008
概括
联合他类药物和尼亚治疗改善了冠状动脉疾病患者的高密度脂蛋白 (HDL) 蛋白质组成. 这种疗法部分逆转了HDL蛋白质的变化,使其更像健康个体.
科学领域:
- 心血管疾病研究研究
- 脂质代谢 脂质代谢是什么
- 蛋白质组学是指蛋白质组学.
背景情况:
- 低高密度脂蛋白 (HDL) 水平是预防心血管疾病的目标.
- 在冠状动脉疾病 (CAD) 患者的HDL(3) 显示在阿波利波蛋白E和改变的蛋白质载荷中的丰富.
- 改变的HDL蛋白质组成可能会影响其抗动脉增生和抗炎功能.
研究的目的:
- 调查结合他类药物和氨酸治疗是否会增加HDL水平,可以逆转CAD受试者改变的HDL蛋白质组成.
- 为了确定这种组合疗法是否使HDL蛋白质组正常化,使其与健康个体的HDL蛋白质组相对应.
主要方法:
- 使用液体染色学 - - 里埃转换 - - 质谱学分析HDL(3) 蛋白质组成,在联合治疗1年之前和之后对CAD患者进行分析.
- 通过光谱计数和提取的离子染色图来量化蛋白质变化.
- 在单独的CAD患者队列中对阿波利波蛋白E水平变化的生物化学验证.
主要成果:
- 组合疗法显著降低了HDL中的阿波利波蛋白E丰度.
- 该疗法增加了参与逆胆固醇运输的巨细胞蛋白的丰富性.
- 在接受治疗的CAD患者中,HDL(3) 蛋白质组更接近健康对照组的蛋白质组.
结论:
- 联合他类药物和尼亚治疗部分扭转了冠状动脉疾病中异常的HDL(3) 蛋白质组成.
- 测量HDL蛋白质组可以提供针对预防动脉样硬化的疗法有效性的见解.
相关概念视频
01:06Lipid Digestion
73.4K
Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
73.4K
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
01:29Cholesterol: Significance and Regulation
2.1K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
2.1K
01:29Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
01:26Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
01:25Lipid Catabolism
1.4K
Triglycerides serve as crucial long-term energy storage molecules in microorganisms, providing a dense source of metabolic energy. Their breakdown is mediated by lipases, which hydrolyze triglycerides into glycerol and free fatty acids. Each of these components follows distinct metabolic pathways, ultimately contributing to ATP synthesis and cellular energy homeostasis.Glycerol MetabolismGlycerol, released from triglyceride hydrolysis, is phosphorylated by glycerol kinase to form...
1.4K